CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010, ...
A new Cochrane review demonstrates that vaccines for respiratory syncytial virus (RSV) are both safe and effective in protecting vulnerable groups that are most at risk of serious illness, including ...
Researchers found that RSV protein subunit vaccines probably reduce RSV-related hospitalization (vaccine efficacy, 83.3%) and severe RSV illness (vaccine efficacy, 94.1%) in older adults. HealthDay ...
The review demonstrates that vaccines for respiratory syncytial virus (RSV) are both safe and effective in protecting groups who are most at risk for serious illness, including older adults and ...
The American College of Physicians (ACP) issued updated vaccine practice points for physicians that advise adults aged 75 or older should receive a protein subunit Respiratory Syncytial Virus (RSV) ...
A new Cochrane review demonstrates that vaccines for respiratory syncytial virus (RSV) are both safe and effective in protecting vulnerable groups that are most at risk of serious illness, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results